QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: jpet.103.063867v1 jpet.103.063867v2 309/3/1060    most recent Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Silakova, J. M. Articles by Hewett, S. J. Search for Related Content PubMed PubMed Citation Articles by Silakova, J. M. Articles by Hewett, S. J.

NEUROPHARMACOLOGY

Naproxen Reduces Excitotoxic Neurodegeneration in Vivo with an Extended Therapeutic Window

Department of Neuroscience, Programs in Cellular and Molecular Pharmacology and Neuroscience, University of Connecticut School of Medicine, Farmington, Connecticut

The purpose of this study was to examine the optimal dose and therapeutic window of opportunity of the nonsteroidal anti-inflammatory drug naproxen in an animal model of excitotoxic neuronal injury. Injection of N-methyl-D-aspartate (NMDA; 18-20 nmol) into the CA1 region of the left hippocampus resulted in significant brain edema as measured by the percentage of total forebrain water content that occurred 24 h after intrahippocampal microinjection of NMDA with 50% loss of CA1 neurons assessed 72 h later. Naproxen pretreatment (20 mg/kg) resulted in significantly less brain edema. Ten, 15, or 20 mg/kg naproxen, administered systemically 1 day (b.i.d.) before and for 3 days after (b.i.d.) NMDA injection, attenuated the neuronal damage by 27.2 ± 7.8, 39.6 ± 11.1, and 57.0 ± 5.2%, respectively. By comparison, a single dose of MK-801 (2 mg/kg i.p.) given 20 min before NMDA injection inhibited subsequent hippocampal injury by 65.6 ± 8.8%. Most importantly, neuroprotection was still evident when naproxen treatment (20 mg/kg i.p.) was initiated 6 h after NMDA microinjection. Protection was lost if administration of naproxen was delayed for 20 h. These findings demonstrate that naproxen can prevent excitotoxic neuronal injury in vivo, that it is nearly as effective as direct NMDA receptor antagonism, and that it has an extended therapeutic time window. As such, naproxen may be a particularly promising pharmaceutical for the treatment of neurological diseases associated with overactivation of NMDA receptors.

Address correspondence to: Dr. Sandra J. Hewett, University of Connecticut Health Center, Department of Neuroscience, MC-3401, 263 Farmington Ave., Farmington, CT 06030-3401. E-mail: shewett{at}neuron.uchc.edu

This article has been cited by other articles:

				S. J. Hewett, J. M. Silakova, and J. A. Hewett Oral Treatment with Rofecoxib Reduces Hippocampal Excitotoxic Neurodegeneration J. Pharmacol. Exp. Ther., December 1, 2006; 319(3): 1219 - 1224. [Abstract] [Full Text] [PDF]